Potential Risks of Using AI Tools for Drug Selection Without Medical Supervision
Hussam Mezher Merdas
Hasan Allawi Sabbar
Special Issue Information
Dear Colleagues,
The rapid advancement of artificial intelligence (AI) in the healthcare and pharmaceutical sectors has led to the development of powerful tools capable of analyzing clinical data, identifying potential treatments, and even recommending specific drugs. While these tools hold great promise in supporting healthcare systems and enhancing decision-making, their use without appropriate medical supervision poses significant risks.
This Special Issue, "Potential Risks of Using AI Tools for Drug Selection Without Medical Supervision", aims to explore the scientific, ethical, and regulatory challenges associated with unsupervised AI-based medication selection. We welcome original research articles, reviews, and case studies focusing on the limitations and unintended consequences of AI-driven drug recommendations, especially in the absence of clinical evaluation by healthcare professionals.
Topics of interest include, but are not limited to:
Biases and limitations in AI drug recommendation systems
Case studies of adverse outcomes from AI-assisted self-medication
The role of explainability and transparency in clinical AI tools
Legal and ethical implications of unsupervised AI in pharmacotherapy
Integration frameworks for safe human–AI collaboration in treatment planning
Public health perspectives on the accessibility and misuse of AI in medicine
This Special Issue invites interdisciplinary contributions from researchers in chemical engineering, pharmaceutical sciences, biomedical informatics, medical ethics, and regulatory policy. Our goal is to raise awareness, foster discussion, and propose solutions to mitigate the risks of using AI in sensitive, health-related contexts without adequate human oversight.
Hussam Mezher Merdas
Guest Editor
